You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

Harbour BioMed, a global biopharmaceutical company, has entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd.

Dublin, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The "Next Generation Drug Conjugates Market Industry Trends and Global Forecast to 2035, by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, ...

Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

Propelled by $94 million in series A financing, Firefly Bio emerged from stealth mode on Feb. 15. The firm will develop a new modality of cancer medicines called degrader-antibody conjugates (DACs).

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Improved Linker and Payload Selection: The selection of suitable linkers and cytotoxic payloads greatly impacts ADC stability, efficacy, and safety. Next-generation ADCs aim to employ novel linkers ...

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports. In the recent years, antibody-drug conjugates (ADC) have been gradually gaining ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...

North America dominated the Antibody Drug Conjugates (ADC) market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period. By ...